- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01930110
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes
An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The objective is to compare the efficacy of single-hormone closed-loop strategy and dual-hormone closed-loop strategy at regulating glucose levels during continuous exercise and interval exercise.
The investigator hypothesized that dual-hormone closed-loop strategy is superior to single-hormone closed-loop strategy in regulating glucose levels during exercise periods.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
We aim to conduct a randomized two-way cross-over trial comparing single-hormone closed-loop strategy and dual-hormone closed-loop strategy to compare the two interventions during exercise periods in adults with type 1 diabetes. A moderate intensity exercise will be performed for 60 minutes at 60% of the maximum oxygen consumption (VO2max). A high intensity exercise will be 40 minutes of interval training. The interval training will be preceded by a 10 minutes warm-up and followed by a 10 minutes cool down.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1R7
- Institut de Recherches Cliniques de Montreal
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Males and females ≥ 18 years of old.
- Clinical diagnosis of type 1 diabetes for at least one year.
- The subject will have been on insulin pump therapy for at least 3 months.
- Last (less than 3 months) HbA1c ≤ 12%.
Exclusion Criteria:
- Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.
- Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
- Ongoing pregnancy.
- Severe hypoglycemic episode within two weeks of screening.
- Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation).
- Failure to comply with team's recommendations (e.g. not willing to eat snack, not willing to change pump parameters, etc).
- Problems with venous access
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Single-hormone closed-loop system
In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
|
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max.
Patients will be discharged at 20:00.
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 40-minute interval exercise.
Patients will be discharged at 20:00.
|
Aktiv komparator: Dual-hormone closed-loop system
In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
|
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max.
Patients will be discharged at 20:00.
Patients will be admitted at the research clinical facility at 14:30.
Closed-loop strategy will start at 15:30.
At 18:00, patients will performed a 40-minute interval exercise.
Patients will be discharged at 20:00.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The number of patients experiencing exercise-induced hypoglycemia requiring dextrose infusion (< 3.3 mmol/L symptomatic or < 3.0 mmol/L regardless of symptoms).
Tidsramme: 18:00 hours to 19:30 hours
|
18:00 hours to 19:30 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Decrease in glucose levels during each exercise
Tidsramme: 18:00 to 19:30 hours or 18:00 to 19:10 depending on the exercise performed
|
Difference between glucose levels at the beginning of the exercise and the lowest glucose level from the start of the exercise until 30 minutes after exercise).
|
18:00 to 19:30 hours or 18:00 to 19:10 depending on the exercise performed
|
Area under the curve of plasma glucose levels < 4 mmol/L
Tidsramme: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Percentage of time of plasma glucose levels < 4 mmol/L
Tidsramme: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L
Tidsramme: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Decremental area under the curve from the start of the exercise for 90 minutes.
Tidsramme: 18:00 to 19:30
|
18:00 to 19:30
|
|
Percentage of time-in-target defined as between 4 and 10 mmol/L
Tidsramme: 15:30 hours to 19:30 hours
|
15:30 hours to 19:30 hours
|
|
Mean time (minutes) to the first hypoglycemic event during the exercise period
Tidsramme: 18:00 to 19:00
|
18:00 to 19:00
|
|
The amount of dextrose infused
Tidsramme: 15:30 to 19:30
|
15:30 to 19:30
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CLASS-06
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordFullførtFysisk aktivitet | Mental helse velvære 1 | Kognitiv funksjon 1, sosial | Academic Attainment | Fitness TestingStorbritannia
-
IpsenAvsluttet
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekreft | Solide svulster | Programmert celledød-1 (PD1, PD-1) | Programmert celledød 1 ligand 1 (PDL1, PD-L1) | Programmert celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
Rambam Health Care CampusIsrael Science FoundationFullført
-
Alvotech Swiss AGFullført
-
PfizerFullført
-
Stony Brook UniversityFullført
-
SanionaFullført
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionFullført
-
Calliditas Therapeutics ABFullført
Kliniske studier på 60-minute exercise
-
Region Örebro CountyRekrutteringMekanisk ventilasjon | Atelektase | Distribusjon av ventilasjonSverige
-
Winthrop University HospitalAvsluttet
-
Grünenthal GmbHFullførtSmerte | Kronisk smerte | Nevropatisk smerte | Visceral smerteTyskland
-
Vifor (International) Inc.Labcorp Drug Development IncTilbaketrukketBeta-thalassemiForente stater, Bulgaria, Israel
-
St. Luke's Rehabilitation InstituteWashington State UniversityRekrutteringSlag | Traumatisk hjerneskade | Ikke-traumatisk hjerneskadeForente stater
-
Barry LondonAvsluttetHjertefeil | Høyre bunt-grenblokkForente stater
-
Vanderbilt UniversityFullførtParkinsons sykdomForente stater
-
University of BathBiotechnology and Biological Sciences Research CouncilFullførtVitamin d | Akutt treningStorbritannia
-
Sobi, Inc.AvsluttetTrombocytopeniForente stater
-
Lee's Pharmaceutical LimitedSuspendertAntiblodplatemedisinKina